Prophylactic Anti-allergic Drug Administration to Prevent Docetaxel and Cyclophosphamide-induced Skin Toxicity: Sub-analysis of a Multiinstitution Neoadjuvant Chemotherapy Trial in Primary Breast Cancer Patients

Abstract

TC and HER-TC are well known to cause skin eruption, indicating that they have a degree of non-hematological toxicity. However, the cause of this toxicity is unclear, and reliable treatment methods have not yet been established. As a result, prophylactic methods to prevent TC/ HER-TC-related skin eruption are urgently needed. Anti-allergic drugs are sometimes administered to treat skin eruption, but their prophylactic effectiveness has not yet been investigated. We hypothesized that the prophylactic use of anti-allergic drugs would decrease the incidence of TC/HER-TC-related skin eruption. We have already reported the